SEC Form 4 · accession 0001493152-26-041130
Ernexa Therapeutics Inc. · ERNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanjeev Luther
Officer — President and CEO · Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 1, 2026 · 9:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000748592
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.57 | Aug 31, 2026 | A | 118,848 | A | — | Aug 31, 2036 | Common Stock | 118,848 | 118,848 | D |
Explanation of responses
- F1Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.